
Augmedix, Inc.
Augmedix, Inc. (AUGX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
augx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Healthcare Information Services · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Augmedix, Inc.You AUGX | $116M | N/A | — | — |
Cyteir Therapeutics, Inc. CYT | $109M | N/A | — | -$1.25 |
Decibel Therapeutics, Inc. DBTX | $123M | N/A | — | -$2.52 |
Five Star Senior Living Inc. FVE | $98M | N/A | — | -$0.94 |
Graybug Vision, Inc. GRAY | $121M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Augmedix, Inc. (AUGX) measures how much investors pay for each dollar of the company's trailing earnings. AUGX's current PE ratio of N/A is calculated by dividing its stock price of $2.35 by its TTM earnings per share of —.
Frequently asked questions
AUGX pe ratio · 6 questionsAUGX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.35 and TTM EPS of —. Data sourced from Financial Modeling Prep via AUGX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Augmedix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09